ERBB2 and metastatic malignant neoplasm in the lymph nodes: Subgroup analysis revealed that TβRII expression was associated with a shorter DFS rate in patients with lymph node metastasis, ER-positive, PR-positive, and Her-2-negative tumors (P = 0.006, P = 0.016, P = 0.022, and P = 0.033, respectively; log rank test; Fig 3A–3D).